About Rama SmartSearch
RamaOnHealthcare brings signal to noise to keep you up-to-date with the latest healthcare industry news. We continuously refine our search algorithm to help you quickly and easily find the most relevant and human-vetted content from the best sources and authors.
Smart Topics: Rama SmartSearch identifies popular industry keywords as "Smart Topics" and searches article titles for related industry keywords.
You may simply combine keywords to narrow search results. Alternatively, you may use the "AND" operator to also combine keywords.
You may use the "OR" operator to broaden search results to match one or more keywords. Alternatively, you may use the "|" operator to also broaden search results.
You may use quotes to find exact matches, where the keywords are matched in order.
You may use the dash operator to exclude keywords and quoted exact matches from search results.
STAT August 1, 2024
Eli Lilly’s obesity drug Zepbound cut the risk of complications and improved symptoms in patients with a common type of heart failure, making it the second GLP-1 drug to show positive results in the disease area after Novo Nordisk’s Wegovy.
The Phase 3 trial studied patients who had heart failure with preserved ejection fraction (or HFpEF) and obesity. Some participants also had type 2 diabetes. Over two years, Zepbound cut...
